Lessons from basic research for PD treatment

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 3, 2005, Pages

  Jörres, Achim ^a   Witowski, Janusz ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Peritoneal membrane

Indexed keywords

CA 125 ANTIGEN; CYTOKINE; GLUCOSE DEGRADATION PRODUCT; GROWTH FACTOR; PERITONEAL DIALYSIS FLUID;

ANGIOGENESIS; CELL CULTURE; CELL FUNCTION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; FIBROBLAST; FIBROSIS; HEMODIALYSIS PATIENT; HUMAN; MEMBRANE BIOLOGY; MESOTHELIUM CELL; NONHUMAN; PERITONEAL BIOPSY; PERITONEAL DIALYSIS; PERITONEUM; PERITONITIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; UREMIA;

EID: 21244501335     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502503s09     Document Type: Review

References (16)

1. Duwe AK, Vas SI, Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 1981; 33:130-5.
2. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990; 37:1563-70.
3. Jörres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, et al. Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines. J Am Soc Nephrol 1996; 7:2192-201.
4. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int Suppl 1994; 48:S71-8.
5. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47:282-93.
6. Jörres A, Williams JD, Topley N. Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. Perit Dial Int 1997; 17(Suppl2):S42-6.
7. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
8. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348: 403-13.
9. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991; 40:77-9.
10. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
11. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061-7.
12. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
13. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
14. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischets-rieder M, Lage C, et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
15. Mackenzie RK, Holmes CJ, Moseley A, Jenkins JP, Williams JD, Coles GA, et al. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. J Am Soc Nephrol 1998; 9:1499-506.
16. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jörres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19:917-24.